Develops Alpha DaRT, a localized radiation therapy using radioactive sources to treat solid tumors, for use by clinicians treating cancer patients.
20-F for FY2025, filed Mar 9, 2026We are a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of…View ↗
The Alpha DaRT technology employs a series of radioactive sources that are embedded with Radium-224 to enable a controlled, intratumoral…View ↗
We remain focused on performing investigational studies to evaluate the potential efficacy of the Alpha DaRT as a monotherapy and an…View ↗
No revenue reported yet.
20-F for FY2025, filed Mar 9, 2026
The company has not yet commercialized Alpha DaRT. It sees clinical sites as potential end users; term sheets call for Medison to handle marketing and distribution in Canada and Israel, and an agreement with HekaBio covers distribution in Japan.
20-F for FY2025, filed Mar 9, 2026We have yet to commercialize in any geographical market, even though we presently have received marketing approval in Israel for the…View ↗
We also believe that our clinical trials being conducted in leading sites around the world will ultimately serve our commercial purposes as…View ↗
While we ultimately envision leading much of the commercialization of the Alpha DaRT in core markets such as the United States, we may…View ↗
In March 2026, we entered into a commercial agreement with HekaBio K.K. related to the distribution of the Alpha DaRT in Japan, providing…View ↗
Competes with Varian Medical Systems, Elekta, BTG, ViewRay, Accuray, RefleXion Medical, Nanobiotix, Novocure, Bayer, Novartis, Fusion Pharmaceuticals, RayzeBio, Actinium Pharmaceuticals, Perspective Therapeutics, RadioMedix, Orano, and Telix Pharmaceuticals
20-F for FY2025, filed Mar 9, 2026In the field of local therapy for solid tumors, we face competition from new or continually improving surgical techniques, as well as a…View ↗
Loading...